S 1378

Access to Medical Treatment Act of 2001

Congress: 107 (2001–2003, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Aug 3, 2001
Current Status: Sponsor introductory remarks on measure. (CR S2965)
Latest Action: Sponsor introductory remarks on measure. (CR S2965) (Apr 18, 2002)
Official Text: https://www.congress.gov/bill/107th-congress/senate-bill/1378

Sponsor

Name: Sen. Daschle, Thomas A. [D-SD]
Party: Democratic • **State:** SD • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Harkin, Tom [D-IA]	D · IA		Aug 3, 2001
Sen. Hatch, Orrin G. [R-UT]	R · UT		Aug 3, 2001
Sen. Inouye, Daniel K. [D-HI]	D · HI		Aug 3, 2001
Sen. Johnson, Tim [D-SD]	D · SD		Aug 3, 2001
Sen. Reid, Harry [D-NV]	D · NV		Aug 3, 2001

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Aug 3, 2001

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
107 HR 1964	Related bill	**Jun 8, 2001:** Referred to the Subcommittee on Health.

Summary (as of Aug 3, 2001)

Access to Medical Treatment Act of 2001 - Defines: (1) "danger" as an adverse reaction to an unapproved drug or medical device that used as directed causes serious harm which would not otherwise have occurred, or harm more serious than side effects for drugs or medical devices approved by the Federal Food and Drug Administration (FDA) for the same disease or condition; and (2) other terms as used in this Act, including "health care practitioner" and "unapproved drug or medical device."

Allows a patient to receive, and the practitioner to provide or administer, any unapproved drug or medical device the patient or their legal representative desires, provided certain conditions are met. Sets forth circumstances under which a health care practitioner may recommend, provide, or administer an unapproved drug or medical device.

Requires a practitioner who discovers that an unapproved drug or medical device creates a danger to a patient immediately to cease use and recommendation of such drug or device and provide specified information to its manufacturer and the Director of the Centers for Disease Control and Prevention. Requires the manufacturer that receives such information to: (1) immediately cease sale and distribution of the drug or device; and (2) comply with specified notification and reporting requirements. Sets forth certain investigative and reporting duties that the Director, the Secretary of Health and Human Services, and a practitioner must perform with respect to the dangerousness or effectiveness of unapproved drugs or medical devices.

Sets forth a penalty for violations of this Act.

Actions Timeline

- **Apr 18, 2002:** Sponsor introductory remarks on measure. (CR S2965)
- **Aug 3, 2001:** Introduced in Senate
- **Aug 3, 2001:** Sponsor introductory remarks on measure. (CR S8951-8952)
- **Aug 3, 2001:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.